The White House has announced the United States will start rolling out COVID-19 booster shots in late September to shore up protection against more transmissible variants. But the move has raised questions about the scientific and ethical basis for the decision, with some experts calling it premature.
Americans will be eligible to receive a third shot of the Pfizer or Moderna vaccines eight months after receiving their second dose. People who received the single-dose Johnson & Johnson vaccine will probably need boosters too but are not yet eligible pending further data.
The announcement came a few days after the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) recommended COVID-19 booster shots for people with compromised immune systems. However, those agencies still need to evaluate the safety and effectiveness of a third shot for the rest of the population before the booster program starts.
Why is the U.S. moving ahead on third shots?
Federal officials say they’re launching the booster program to stay one step ahead of breakthrough infections among fully vaccinated people. They noted that COVID-19 vaccines are still highly effective, but their protection against infection appears to be waning.
“Fortunately, the vast majority of [breakthrough infections] are quite mild and what we really want to prevent is that turning into people being sick enough to be in the hospital,” U.S. National Institutes of Health Director Dr. Francis Collins told CBC Power & Politics. “There is a hint that we might be on the path towards that, and it looks like in course of the next month or two that’s going to become more of an issue.”
Data from the New York State Department of Health, the Mayo Clinic and the CDC’s reporting system for nursing homes showed declining protection against infection but no significant changes in severe disease or hospitalizations among fully vaccinated people.
However, as of August 15, Israel reported 514 hospitalizations for severe or critical COVID-19 – up 31% from four days earlier – and nearly three in five of those patients were fully vaccinated. That country is now offering booster shots to people over 50.
According to U.S. President Joe Biden, “We have a responsibility to give the maximum amount of protection.” He also noted that additional shots are “the best way to protect ourselves from new variants that could arise.”
Some experts have noted that logistics may also factor in the decision, as it may take months to get the booster program up to full speed, even after the September start date.
What’s the evidence supporting the decision?
White House officials presented evidence from several recent studies on infections among fully vaccinated people.
One study of residents at nearly 15,000 long-term care facilities found that the protection against infection offered by the Pfizer and Moderna vaccines dropped from 74% in the spring to 53% this summer. The authors counted infections with no symptoms in their analysis and didn’t look at whether vaccine effectiveness against serious illness had changed.
A New York state study that also included people who received the Johnson & Johnson shot likewise reported a drop in protection against lab-confirmed infection from 92% in early May to 80% in late July. However, effectiveness against COVID-19 requiring hospitalization held steady at about 95%.
Meanwhile, a pre-print Mayo Clinic analysis of more than 80,000 Americans found the Pfizer shot was only 42% effective against SARS-CoV-2 infection in July, while Moderna’s was 76% effective. Even so, protection against hospitalization remained high at 75% and 81%, respectively.
These findings indicate that COVID-19 vaccines are still doing an excellent job keeping fully immunized people out of the hospital, even if larger numbers are testing positive for SARS-CoV-2 infection (many of whom may have no symptoms).
According to the authors of the New York state study, multiple factors may contribute to the apparent decline in vaccine effectiveness against infection – from the spread of more transmissible variants to the easing of mask mandates and other public health precautions over the spring and summer. At the same time, a growing proportion of unvaccinated people may have some level of protection from prior infection or from having more vaccinated people around them.
Where does Canada stand on booster shots?
Canada’s National Advisory Committee on Immunization has not yet made a formal recommendation on COVID-19 booster shots but is examining vaccine effectiveness in people with compromised immune systems. According to NACI, immunocompromised people may require booster shots to produce a comparable immune response to the general population.
A spokesperson for Health Canada and the Public Health Agency of Canada told CMAJ that provinces and territories may choose to offer additional doses to specific populations to enhance their protection against COVID-19. But doing so would be considered off-label use since Health Canada has not authorized a three-dose regimen for any of the COVID-19 vaccines.
Ontario recently announced it will offer third doses to transplant recipients and other people whose immune systems are compromised. These patients will receive boosters at least eight weeks after their second shot.
Third doses will also be available five months after immunization to residents of long-term care facilities, First Nations eldercare lodges and “higher-risk” retirement homes, although it is unclear what homes fall into this last category.
Dawn Bowdish, Canada Research Chair in ageing and immunity, has been following vaccine effectiveness in long-term care residents in Ontario, most of whom were vaccinated early this year. In a pre-print study looking at residents in eight nursing homes between March and July, about one in five had no neutralizing antibodies against the virus, suggesting that they may need a different vaccination regimen to achieve the same protection as the general population.
Bowdish and colleague’s paper was one of several that informed Ontario’s booster policy. In a complementary pre-print study, Toronto researchers looked at residents in long-term care homes and found they had a much less robust immune response and fewer neutralizing antibodies than vaccinated staff.
However, Bowdish cautioned against extrapolating from older adults to the general population because people in long-term care are “very immunologically vulnerable.”
Why do some experts think it’s premature to offer booster shots?
According to Bowdish, the data supporting booster shots for the general population is “sparse and frankly, in Canada, it’s not existent yet.” She added that the U.S. decision seemed based on the recent reports of hospitalizations in Israel, most of which were among seniors, rather than on the local data on mostly mild and asymptomatic breakthrough infections.
Dr. Zain Chagla, an infectious disease physician at St. Joseph’s Healthcare Hamilton and associate professor at McMaster University, agreed that the evidence for a general booster shot program is “not necessarily there yet, but it probably does need to be in the cards in the next six months to a year.”
Over the next few months, Canadian jurisdictions will need to monitor breakthrough cases, particularly in vulnerable populations, he said.
South of the border, some experts argue it doesn’t make sense to offer booster shots while many people are still unvaccinated and COVID-19 vaccines are still highly effective.
According to Dr. Celine Gounder, an infectious disease specialist and epidemiologist at the NYU School of Medicine, improving overall vaccine uptake would offer greater community protection than giving booster shots to vaccinated people.
Protection against serious disease may also last much longer than protection from infection, Gounder told NPR. “Injected vaccines like we have for COVID induce good systemic immunity in the main organs of the body,” meaning that breakthrough upper-respiratory infections typically won’t progress into serious illness affecting the lungs and other organs.
Memory B cells and T cells play a crucial role in fighting off severe disease but are more difficult to measure than the antibody immunity involved in preventing infection.
“The T cells generated by the vaccines are holding up amazingly well, with [up to] 99% of the hospitalizations being among unvaccinated adults in the US,” tweeted Dr. Monica Gandhi, an infectious disease physician at the University of California San Francisco.
Others, including a former FDA director of vaccines research, have noted that the U.S. appears to be putting the cart before the horse by setting a September launch date when health authorities haven’t evaluated the safety and effectiveness of the proposed booster program.
Pfizer only applied to the FDA to approve a third shot on Aug. 16 and the agency hasn’t evaluated that application yet. Moderna hasn’t filed an application. Meanwhile, the CDC’s independent vaccine advisory committee won’t start evaluating the data on booster shots until next week.
Some also argue it’s unethical to give boosters to prevent mild illness and asymptomatic infections in vaccinated people when many countries still have limited access to COVID-19 vaccines.
“Presently, in Canada, we have procured more vaccine doses than our population needs for every eligible adult and child over age 12. That being the case, now is the time to send excess doses to jurisdictions around the globe where no vaccines are available,” said Eleanor Fish, a professor of immunology at the University of Toronto.